Posters

Background: Valbenazine is approved for the treatment of tardive dyskinesia (TD), a persistent and disabling movement disorder associated with prolonged antipsychotic exposure. Data from KINECT 3 were analyzed post hoc to evaluate changes in TD (based on Abnormal Involuntary Movement Scale [AIMS])…

Background: Oral antipsychotic medications (OAMs) are frequently prescribed to patients with bipolar I disorder (BD-1) for symptom control. A cross-sectional survey examined side effects experienced with OAM and the perceived impacts of these side effects among patients living with BD-1. Methods:…

Background: Tardive dyskinesia (TD) is a debilitating, often-irreversible hyperkinetic movement disorder that impairs patients’ abilities to perform daily activities. Deutetrabenazine was FDA-approved to treat TD based on the pivotal ARM-TD and AIM-TD studies.

BACKGROUND: Tardive dyskinesia (TD), a movement disorder, may arise in patients taking antipsychotics. Social and professional stigma associated with mild-to-moderate TD movements has not been thoroughly examined. Here we evaluate the professional and social impact of mild-to-moderate orofacial TD…

BACKGROUND: Tardive dyskinesia (TD), a movement disorder that can develop in patients taking antipsychotics, is a potential source of stigma, but this has not been thoroughly examined. Here, we evaluate the impact of moderate-to-severe orofacial TD symptoms on the professional and social lives of…

BACKGROUND: Antipsychotics are commonly used for maintenance treatment of schizophrenia (SZ), bipolar disorder (BP), and major depressive disorder (MDD). Treatment adherence reduces the risk of relapse, but fear of side effects, such as extrapyramidal symptoms (EPS), may prompt medication switching…

Background: Cariprazine is approved to treat manic, mixed, and depressive symptoms of bipolar I disorder. This analysis describes the efficacy and tolerability of cariprazine in bipolar I disorder using clinically relevant metrics of number needed to treat (NNT) and harm (NNH).

Background: Valbenazine, a novel and highly selective VMAT2 inhibitor, is approved for the treatment of TD in adults. Data from two long-term studies (KINECT 3 [K3], KINECT 4 [K4]) and a roll-over study (1506) were analyzed to better understand the effectiveness of valbenazine in patients who…

Background: The elevated prevalence of metabolic syndrome (MetS) in patients with depression has been associated with increased mortality rates. The aim of this post-hoc analysis was to assess the effect of treatment with lurasidone on risk of MetS in patients with bipolar depression.

Background: The impact of possible tardive dyskinesia (TD) was assessed in RE KINECT, a real-world study of antipsychotic-treated outpatients. Based on clinician assessments, patients were assigned to Cohort 1 (no involuntary movements, N=450) or Cohort 2 (clinician-confirmed possible TD, N=204).…